-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Enuo//ku6NeJ46GLmSG9+yWOkl4ja+jvhvjTjqYCG6uQcT8gR8+HZz9uExpm0tzs
 n3hbI+gIPEgOZP9rys2VNg==

<SEC-DOCUMENT>0001104659-09-036887.txt : 20090605
<SEC-HEADER>0001104659-09-036887.hdr.sgml : 20090605
<ACCEPTANCE-DATETIME>20090605140349
ACCESSION NUMBER:		0001104659-09-036887
CONFORMED SUBMISSION TYPE:	D
PUBLIC DOCUMENT COUNT:		1
ITEM INFORMATION:		Rule 506
FILED AS OF DATE:		20090605
DATE AS OF CHANGE:		20090605
EFFECTIVENESS DATE:		20090605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIMERICK BIOPHARMA INC
		CENTRAL INDEX KEY:			0001358877
		IRS NUMBER:				061735053
		STATE OF INCORPORATION:			CA

	FILING VALUES:
		FORM TYPE:		D
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	021-88136
		FILM NUMBER:		09876579

	BUSINESS ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD
		STREET 2:		#700
		CITY:			SO. SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-742-0110

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD
		STREET 2:		#700
		CITY:			SO. SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIMERICK NEUROSCIENES INC
		DATE OF NAME CHANGE:	20060410
</SEC-HEADER>
<DOCUMENT>
<TYPE>D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<edgarSubmission>

    <schemaVersion>X0401</schemaVersion>

    <submissionType>D</submissionType>

    <testOrLive>LIVE</testOrLive>

    <primaryIssuer>
        <cik>0001358877</cik>
        <entityName>LIMERICK BIOPHARMA INC</entityName>
        <issuerAddress>
            <street1>601 Gateway Boulevard, Suite 700</street1>
            <city>So. San Francisco</city>
            <stateOrCountry>CA</stateOrCountry>
            <zipCode>94080</zipCode>
        </issuerAddress>
        <issuerPhoneNumber>650-742-0110</issuerPhoneNumber>
        <issuerPreviousNameList>
            <previousName>Efflux Technology, Inc.</previousName>
            <previousName>Limerick Neurosciences, Inc.</previousName>
        </issuerPreviousNameList>
        <jurisdictionOfInc>CALIFORNIA</jurisdictionOfInc>
        <entityType>Corporation</entityType>
        <yearOfInc>
            <withinFiveYears>true</withinFiveYears>
            <value>2004</value>
        </yearOfInc>
    </primaryIssuer>

    <relatedPersonsList>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Wendye</firstName>
                <middleName></middleName>
                <lastName>Robbins</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>601 Gateway Boulevard, Suite 700</street1>
                <city>So. San Francisco</city>
                <stateOrCountry>CA</stateOrCountry>
                <zipCode>94080</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Asha</firstName>
                <middleName></middleName>
                <lastName>Rajagopal</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>601 Gateway Boulevard, Suite 700</street1>
                <city>So. San Francisco</city>
                <stateOrCountry>CA</stateOrCountry>
                <zipCode>94080</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Stephen</firstName>
                <middleName>M.</middleName>
                <lastName>Dow</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>601 Gateway Boulevard, Suite 700</street1>
                <city>So. San Francisco</city>
                <stateOrCountry>CA</stateOrCountry>
                <zipCode>94080</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Corey</firstName>
                <middleName>S.</middleName>
                <lastName>Goodman</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>601 Gateway Boulevard, Suite 700</street1>
                <city>So. San Francisco</city>
                <stateOrCountry>CA</stateOrCountry>
                <zipCode>94080</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Scott</firstName>
                <middleName></middleName>
                <lastName>Minick</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>601 Gateway Boulevard, Suite 700</street1>
                <city>So. San Francisco</city>
                <stateOrCountry>CA</stateOrCountry>
                <zipCode>94080</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
    </relatedPersonsList>

    <offeringData>
        <industryGroup>
            <industryGroupType>Biotechnology</industryGroupType>
        </industryGroup>
        <issuerSize>
            <revenueRange>Decline to Disclose</revenueRange>
        </issuerSize>
        <federalExemptionsExclusions>
            <item>06</item>
        </federalExemptionsExclusions>
        <typeOfFiling>
            <newOrAmendment>
                <isAmendment>false</isAmendment>
            </newOrAmendment>
            <dateOfFirstSale>
                <value>2009-06-01</value>
            </dateOfFirstSale>
        </typeOfFiling>
        <durationOfOffering>
            <moreThanOneYear>false</moreThanOneYear>
        </durationOfOffering>
        <typesOfSecuritiesOffered>
            <isDebtType>true</isDebtType>
            <isOptionToAcquireType>true</isOptionToAcquireType>
            <isSecurityToBeAcquiredType>true</isSecurityToBeAcquiredType>
        </typesOfSecuritiesOffered>
        <businessCombinationTransaction>
            <isBusinessCombinationTransaction>false</isBusinessCombinationTransaction>
            <clarificationOfResponse></clarificationOfResponse>
        </businessCombinationTransaction>
        <minimumInvestmentAccepted>0</minimumInvestmentAccepted>
        <salesCompensationList></salesCompensationList>
        <offeringSalesAmounts>
            <totalOfferingAmount>1500000</totalOfferingAmount>
            <totalAmountSold>1500000</totalAmountSold>
            <totalRemaining>0</totalRemaining>
            <clarificationOfResponse></clarificationOfResponse>
        </offeringSalesAmounts>
        <investors>
            <hasNonAccreditedInvestors>false</hasNonAccreditedInvestors>
            <totalNumberAlreadyInvested>5</totalNumberAlreadyInvested>
        </investors>
        <salesCommissionsFindersFees>
            <salesCommissions>
                <dollarAmount>0</dollarAmount>
            </salesCommissions>
            <findersFees>
                <dollarAmount>0</dollarAmount>
            </findersFees>
            <clarificationOfResponse></clarificationOfResponse>
        </salesCommissionsFindersFees>
        <useOfProceeds>
            <grossProceedsUsed>
                <dollarAmount>0</dollarAmount>
            </grossProceedsUsed>
            <clarificationOfResponse>Funds to be used for general working capital.</clarificationOfResponse>
        </useOfProceeds>
        <signatureBlock>
            <authorizedRepresentative>false</authorizedRepresentative>
            <signature>
                <issuerName>Limerick BioPharma, Inc.</issuerName>
                <signatureName>/s/ Ann Coppel</signatureName>
                <nameOfSigner>Ann Coppel</nameOfSigner>
                <signatureTitle>Sr. Legal Assistant</signatureTitle>
                <signatureDate>2009-06-05</signatureDate>
            </signature>
        </signatureBlock>
    </offeringData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----